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The interaction of donor passenger leukocytes and host leukocytes in recipient secondary lymphoid tissues during the early 
posttransplantation period is crucial in directing host immune reactions toward allograft rejection or acceptance. Responsible 
T cell clones could be activated through the direct and indirect pathways of allorecognition. We examined the role of the indirect 
pathway in liver transplantation (L T) tolerance by depleting host antigen-presenting cells (APC) with phagocytic activity [e.g., 
cluster domain (CD)68 + /CD163 + macrophages, CD11 c+ dendritic cells (DC)] using liposome-encapsulating clodronate 
(LP-CL). After Lewis rat cell or liver graft transplantation, Brown Norway (BN) rat reCipients pretreated with LP-CL showed a 
significantly reduced type 1 helper T cell cytokine up-regUlation than control-LP-treated reCipients, In the L T model, LP-CL 
treatment and host APC depletion abrogated hepatic tolerance; Lewis liver grafts in LP-CL-treated-BN recipients developed 
mild allograft rejection, failed to maintain donor major histocompatibility complex (MHC) class" + leukocytes, and developed 
chronic rejection in challenged donor heart allografts, while control-LP-treated BN recipients maintained tolerance status and 
donor MHC class" + hepatic leukocytes. Furthermore, in the BN to Lewis L T model, LP-CL recipient treatment abrogated 
spontaneous hepatic allograft acceptance, and graft sUNival rate was reduced to 43% from 100% in the control-LP group. In 
conclusion, the study suggests that host cells with phagocytic activity could play Significant roles in developing L T tolerance. 
Liver Transpl 14:346-357. 2008. ",2008 AASLD. 
Received June 1, 2007; accepted September 30, 2007. 
Bone marrow-derived "passenger" leukocytes in solid 
organs migrate to recipient secondary lymphOid tissues 
after transplantation, and their subsequent interac-
tions with reCipient leukocytes during the early post-
transplantation period appear to be crucial in directing 
host immune reactions toward allograft rejection 
and/or graft acceptance, 1-7 An essential role of host 
secondary lymphoid tissues in providing a microenvi-
ronment for the interaction of host T cells and migrating 
donor leukocytes has been substantiated in splenecto-
mized aly/ aly (alymphoplastic) mice that lack second-
ary lymphoid tissues and fail to reject cardiac allo-
grafts. B In host secondary lymphoid organs. 
responsible host T cell clones could be activated by 
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donor and recipient antigen presenting cells (APC) 
through 2 distinct pathways of allorecognition; in the 
direct pathway, recipient T cells recognize intact donor 
major histocompatibility complex (MHC) molecules 
complexed with peptide on the surface of migrating 
clonor APC, while, in the indirect pathway, recipient T 
cells recognize donor-derived allopeptides processed 
and presented in the context of recipient MHC on host 
APC. 'l.1o Historically, the direct pathway has been con-
sidered to playa primary role in initiating alloimmune 
responses during the early posttransplantation period 
and lead to acute rejection. 1 .2. II In contrast. the indi-
rect pathvlay has been shown to play roles in initiating 
cluster domain (CD)4 + T cell responses and mediating 
chronic rejection during a later phase of transplanta-
tion, when donor MHC class II! passenger leukocytes 
disappear from organ allografts. Recently. there has 
been increasing interest in a prominent role of the in-
direct pathway in initiating alloimmune responses dur-
ing the early phase of organ transplantation. s. 12·14 
However, the relative contributions of the direct and 
indirect pathways during the early acute phase of organ 
transplantation in initiating graft rejection and toler-
ance remain largely unclear. 
In vivo administration of lip os orne clodronate (LP-CL) is 
known to selectively and effiCiently deplete mononuclear 
phagocytic cells without affecting other leukocyte popu-
lations. I"· 17 After ingestion via endocytOSiS, liposomes 
encapsulating clodronate are dismpted by lysosomal 
phospholipases. release clodronate within the cell, and 
lead to cell death. The technique has been widely used to 
investigate the in vivo role of phagocytic cells, such as 
macrophages and dendritic cells (DC). in defined biologi-
cal processes. including infection, autoimmunity, graft-
versus-host disease, and transplantation. ls- 2 -lc 
We have previously shown that liver transplantation 
(LT) associates with prompt migration of a large number 
of graft leukocytes into host lymphoid tissues. 25 .26 
However. it remains undetermined how migrating do-
nor leukocytes present alloantigens to host T cells and 
initiate immune reactions. In this study, we attempted 
to paralyze the indirect pathway of allorecognition by 
eliminating host APC with phagocytic activity using the 
LP-CL method. Using animals pretreated with LP-CL as 
recipients, the primary purpose of the study was to 
evaluate in vivo roles of host phagocytes and indirect 
pathway of allorecognition after LT in initiating acute 
rejection and tolerance. 
MATERIALS AND METHODS 
Animals 
Inbred male Lewis (LEW, RI'11), Brown Norway (BN, 
RI'1"), and ACI (RI'1") rats weighing 200 to 250 g were 
obtained from Harlan Sprague Dawley (Indianapolis, IN) 
and maintained in laminar now cages in a specific patho-
gen-free animal facility at the University of Pittsburgh 
\vilh a standard diet and water ad libitum. All procedures 
in this study were performed according to the gUidelines 
of the Council of Animal Care at the University of Pitts-
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burgh within the gUidelines of National Institutes of 
Health and the Public Health Service Policy of the hu-
mane use and care of laboratory animals. 
Monoclonal Antibodies (mAbs) 
Monoclonal anlibodies (mAbs) used in this study included 
purified or fluorescent-conjugated 8A2 (CD 11c), ED I 
(CD68), ED2 (CD 163), R7.3 [al3 T cell receptor], OX33 
(CD45RA: B cell), OX35 (CD4), OX8 (CD8u), OX6 (MHC 
class II) and anti-rat immunoglobulin (IgJM (B cell) (BD 
PharMingen, San Diego, CA or Serotec, Oxford. UK). mAb 
L21-6 (mouse IgG I ) that binds to MHC class II antigens of 
LEW. but not BN, was used to identifY donor MHC class 
W cells. 27 Biotinylated rat anti-mouse IgG, or Cy3 or 
fluorescein isothiocyanate (FITCl-conjugated goat anti-
mOLlse IgG (Jackson ImmunoResearch laboratories, 
Inc., West Grove, PA) were used as secondary antibod-
ies, Isotype-matched irrelevant mAbs were used as neg-
ative controls. 
Organ Transplantation 
OrthotopiC liver transplantation (OLTx) with arterial re-
construction and heterotopiC heart transplantation 
(HTx) into the abdomen were carried out as previously 
described. 26 Liver graft rejection was defined as reCipi-
ent animal survival. Heart graft survival was monitored 
by transabdominal palpation, and rejection was defined 
as the cessation of heartbeat. 
Imm unos u ppression 
Tacrolimus (TAC: Astellas Pharma Inc, Tokyo, Japan) in 
normal saline was injected intramuscularly on days 
0-6, 13, and 20 after OLTx at a dose of 1.0 mg/kg/day. 
This dose ofTAC has been shown to induce long-term 
rat organ allograft survival.26,2R 
Preparation of LP-CL and Recipient 
Treatment 
LP-CL was prepared as previously deSCribed with minor 
modifications. 15-17.29 Briefly, lipids composed of 86 mg 
egg phosphatidylcholine (Avanti Polar Lipids, Alabas-
ter, AL) and 9 mg cholesterol (Sigma-Aldrich, St. Louis, 
MO) were dissolved in 10 mL chloroform, The organiC 
solvent was removed under reduced pressure in a ro-
tary evaporator, and resulting lipid film was desiccated 
and dispersed in 10 mL phosphate buffered saline 
(PBS) containing 2.5 g clodronate (Sigma-Aldrich). The 
liposome was rapidly frozen in liqUid nitrogen and 
slowly thawed at 4°C. The freeze-thaw step was re-
peated 3 times to increase the entrapment efficacy of 
clodronate in the liposome. 2H LP-CL was purified by 3 
centrifugation washes at 1O,000g for 15 minutes, and 
resuspended in 4 mL sterilized PBS, For the controL 
liposome without clodronate was prepared. Control-LP 
or LP-CL (4.0 mL/kg, relevant to 100 mg/kg c1odronate) 
was intravenously injected 2 times to BN reCipients via 
the penal vein on 10 and 7 days before OLTx, 
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Leukocyte Isolation and Purification 
Single-cell suspensions were obtained by injecting Ro-
swell Park Memorial Institute (RPM!) medium into ex-
cised cervical and mesenteric lymph nodes and spleens 
and following filtration through nylon mesh. After red 
blood cell lysis with NH4 CI buffer, T cells were positively 
iso18ted using anti-rat pan-T cell microbeads (OX52) 
and LS columns (Miltenyi Biotec, Germany) with purity 
oC 85 Lo 900A). The non-T cell population, which con-
t8ined 50 to 55% of MHC class Il+ (OX6+) and 60 to 
65°/(l or B (OX33+) cells. was also collected. 
Carboxyfluorescein Succinimidyl Ester (CFSE) 
Labeling 
Carboxyl1uorescein succinimidyl ester (CFSE: Molecu-
lar Probes, Eugene. OR) was used as described for cell 
18beling. with some modifications. Typically, single-cell 
suspensions (l x 107 /mL) were incubated with 5 j..LM 
CFSE for 30 minutes at room temperature. Labeled 
cells were washed 3 times with RPMI medium with 20% 
vol/vol fetal calf serum to eliminate unconjugated 
CFSE. and then resuspended in PBS for injection. 
Experimental Design 
Organ Transplantation 
To examine the influence ofLP-CL-induced host phago-
cyte depletion on allograft survival. LEW liver grafts 
were transplanted into Control-LP- or LP-CL-treated 
BN reCipients with or without TAC immunosuppres-
sion. Animals were followed for 200 days or until allo-
graft rejection. At 100 days. to determine the status of 
allograft acceptance, LEW heart grafts were trans-
planted to surviving liver recipients with a [ollow-up of 
additional 100 days. At the time of sacrifice, graft tissue 
samples were fixed in 10% formalin for routine histo-
pathology. in OCT compound and frozen in liqUid nitro-
gen cooled isopentane for immunohistochemistry, and 
snap-frozen for messenger RNA (mRNA) isolation, The 
host spleen was obtained for flow cytometry. 
Cell Migration 
The influence of LP-CL-induced host phagocyte deple-
tion on early cell migration pattern was studied by in-
fUSing LEW CFSE-Iabeled T cell or non-T cell popula-
tions (2 x 108 cells per animal) into BN reCipients 
treated with Control-LP or LP-CL. Animals were sacri-
ficed at 24 or 72 hours after cell injection for immuno-
histochemical analyses of cell migration and polymer-
ase chain reaction (PCR) for cytokine mRNA levels. No 
immunosuppressive drug was used. 
AllogeniC cell migration in host spleen was also stud-
ied by in vivo real-time confocal fluorescent imaging. 
Naive BN animals received intravenous injection of 0.5 
mL or 0.02 fLm-diameter microspheres containing red 
fluorescent dye (Fluo-Spheres: Molecular Probes] to de-
tect macrophages or DC by phagocytosis. Then. unfrac-
Uonated LEW CFSE-labeled splenocytes were injected 
into recipients 30 minutes after microsphere injection. 
Migration pattern of injected cells in the spleen was 
sequentially visualized by confocal fluorescent imaging 
as described before. 30 At 30 minutes. 4 hours, and 24 
hours after cell injection, animals were anesthetized and a 
small laparotomy was perfom1ecl. The spleen was mobi-
lized and examined with fluorescent confocal microscopy. 
The imaging probe tip was positioned in contact with the 
surface of the spleen. Laser excitation utilized the com-
bined 488 nm/568 nm spectral lines of a 50-mW air-
cooled krypton-argon laser. Migrated CFSE+ cells into the 
spleen were visualized as green using a 505-nm long-pass 
filter for detection (Chroma Technology, Brattlebor, vn. 
Emitted fluorescence from red microspheres contained 
within macrophages or DC by phagocytosis was detected 
using a 585-nm long-pass filter (Chroma Technology). 
Routine Histopathology 
Tissue samples were fixed in 10% butTer iommlin. embed-
ded in paraffm, sectioned at 5 f.Lm, and stained with he-
matoxylin and eosin. In the liver allografts, particular at-
tention was directed to the presence or absence of bile 
duct damage and/ or loss. bile ductular proliferation. sub-
endothelial mononuclear infiltration in the portal or cen-
tral veins, and severity of portai tract inflammation.31.32 
Immunohistochemistry 
Frozen samples were cut into 6-j..Lm sections onto gela-
tin-coated slides and stained with immunoperoxidase 
or immunofluorescent methods. The aVidin-biotin-per-
oxidase immune complex was visualized with 3-amino-
9-ethy1carbazole (AEC: ScyTek Laboratories, Logan. 
UT) and counterstained with hematoxylin, For immu-
nofluorescent staining. after blocking with 10% (voll 
vol) normal goat serum in super block (ScyTek Labora-
tories), the sections were incubated with each primary 
antibody, and then exposed to fluorescent-conjugated 
secondary antibody. Hoechst dye (bisBenzimide. Sigma, 1 
j..Lg/100 mL) was used for 30 seconds to stain nuclear 
DNA. The sections were washed and coverslipped with 
Gelvatol, a water-soluble mounting media (23 g polyvinyl 
alcohol. 50 mL glycerol, 0.01% sodium azide in 100 mL 
PBS), and visualized with an Olympus BX51 epifluores-
cence microscope and digitized with an Olympus color 
video camera (Olympus. Center Valley, PAl. Positively-
stained cells were counted in 4 randomly selected high 
power fields (X400) per section. 
SYBR Green Real-Time Reverse Transcription 
(RT)-PCR 
mRNA for interleukin (IL)-2, IL-lO, interferon (IFN)-r. and 
glyceraldehyde-3-phosphate dehydrogenase were quanti-
fied by SYBR Green real-time reverse transcription (RT)-
PCR as described before,33 After removal of potentially 
contaminating DNA with DNase l. 1 fLg of total RNA from 
each sample was used for RT with an oligonucleotide dT 
and a Superscript II (all from Life Technologies, Grand 
Island. NY]. The PCR reaction mixture was prepared using 
SYBR Green PCR Master Mix (PE Applied Biosystems, 
Foster City. CAl using previously described primers. 34 
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'f11ermal cycling conditions were 10 minutes at 95°C fol-
10vJed by 40 cycles at 95°C for 15 seconds and 60°C for 1 
minute on an ABI-Prism 7000 Sequence Detection Sys-
Lem (PE Applied Biosystems). Each gene expression was 
normalized with glyceraldehyde-3-phosphaLe dehydroge-
nase mRNA content. 
Flow Cytometry 
Lineages or splenocytes from experimental animals were 
analyzed with fluorescent-conjugated mAbs R7.3-FITC, 
OX8-phycoerythlin. OX39-FITC. OX33-FITC, EDI-FITC. 
ED2-FITC. ,md CDllc-FITC. The samples were fixed in 
paraformaldehyde and analyzed on a Coulter Elite ESP 
(Coulter. Miami. FL). Isotype-matched nonspecific anti-
bodies were used for controls. 
Mixed Leukocyte Reaction (MLR) 
One-way mixed leukocyte reaction (MLR) was conducted 
using unlractionated cervical lymph node lymphocytes or 
spleen cells obtained [rom experimental animals. RPMI 
1640 supplemented with 25 mM 4-2-hydroxyethyl-l-
piperazineethanesulfonic acid buffer, 5 x 10-5 M 2-mer-
captoethanol, 2 mM L-glutamine, penicillin (50 U/mL). 
streptomycin (50 }Lg/mL). NG-monomethyl-L-arginine-
HOAc (NMA; Cyc103 Pss Biochemical. State Lake, UTj and 
10% heat-inactivated normal rat serum was used as 
culture medium. For MLR. responder cells [1. 75 x 105 
cells/well) and irradiated (20 Gy) stimulator cells (3 X 
105 cells/well) were placed in round-bottom 96-well 
plates. Cultures were incubated in a humidified atmo-
sphere of 5% CO2 at 37°C for 4 days. Then 1 }LCi of 
:JH-thymidine was added to each well 16 hours before 
the termination of the cultures. Cultures were har-
vested and "H-thymidine incorporation was determined 
in a liqUid scintillation counter. 
Statistical Analysis 
The differences of graft survivals among groups were 
analyzed Llsing the log-rank test. Other data were ex-
pressed as mean::!: standard deviation, and statistical 
analysis was performed with the Student t test or anal-
ysis of variance. A probability level of P < 0.05 was 
considered statistically Significant. 
RESULTS 
Effects of LP-CL on Phagocytic Macrophages 
and Immature DC in the Spleen 
The depleting efficacy of LP-CL was examined at 7 days 
after the second LP-CL injection using immunofluores-
cent staining with mAb ED I. ED2. and CD 11 c. In the 
spleeon of naive and Control-LP-treated animals, abun-
dant ED 1 ' and E02' macrophages were seen (Fig. lA). 
CD 11 e expression also was seen in the red pulp, splenic 
marginal zone. and splenic periarteriolar lymphoid 
sheath (1' cell area). LP-CL treatment sLlccessfully re-
duced the number of ED 1. ED2. and CO llc expressing 
macrophages and DC. The numbers of positively stained 
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cells were reduced to 7 to 22% (EDl, 22%; ED2. 7%; 
CDllc, 15%) of those in Control-LP and naive animals. 
By 30 days after the second injection. ED 1. ED2, and 
CD 11 c positive cells were repopulated with normal fre-
quencies and distributions (data not shown). 'The result 
indicated temporary reduction of macrophages and 
CD llc I DC in the spleen with LP-CL. 
When we examined other secondary lymphoid organs 
(cervical and mesenteric lymph node, and thymus). the 
fi'equencies of ED I , ,ED2+, and COlle I cells were sim-
ilar between naive. Control-LP-treated, and LP-CL-treated 
animals (Supplementary Fig. Sl). The result is consistent 
with previous studies demonstrating that intravenously 
administered LP-CL targets phagocytes in the liver and 
spleen without affecting those in the lymph nodes be-
cause liposomes are not able Lo cross capillaly walls and 
other vascular barriers (e.g .. blood brain barrier).I(i.17 
Flow cytometric analysis of splenocytes showed that 
in LP-CL-treated animals, EDI . ED2', and COlIc' 
cells significantly decreased. while R7.3+, CD4 +, CD8". 
and OX33+ B cell populations marginally increased 
when compared with those of Control-LP-treated or na-
ive animals (Supplementary Fig. S2). Results suggested 
that the elimination of ED 1 +, ED2 +, and CD 11 c + DC 
resulted in a relative percentage increase of other pop-
ulations in flow cytometry (Supplementary Fig. S2). 
Further analysis of T cell function in LP-CL-treated 
animals in MLR revealed that splenocytes from LP-CL-
treated animals had normal proliferative capability 
against allogenic stimulator cells (Fig. 1 B). 
LP-CL Recipient Treatment Did Not Alter 
Allogenic Cell Migration Patterns 
To examine the effects of LP-CL treatment and phagocytic 
cell depletion on the early migration patterns of allogenic 
passenger leukocytes. we first adopted an in vivo confocal 
fluorescent imaging system and conducted real-time 
tracking of infused allogenic CFSE+ cells in the spleen. 
Intravenously infused allogeniC cells were identified in the 
imaging field of the host spleen immediately after infu-
sion. Initially. the majority of CFSE + cells appeared in the 
visuallleid but quickly disappeared from the field without 
lodging, suggesting that CFSE+ cells were in the splenic 
circulation. Nevertheless. a few CFSE+ cells started to 
lodge into the splenic environment soon alter infusion 
(Fig. 2A). Once infused CFSE" cells were lodged, they 
appeared to be fixed and were not relocated. The number 
of lodged cells gradually increased during the first 24 
hours. The results obtained from real-time tracking sug-
gest that infused allogenic cells embed at permanent po-
sitions in the. spleen without repositioning. 
Subsequently, migration patterns and immune re-
sponses were studied at 24 to 72 hours after injection of 
CFSE-labeled T cell or non-T cell populations (2 X lOB 
cells per animal) into BN reCipients treated with Con-
trol-LP or LP-CL without immunosuppression. At 24 
hours after infusion. infused l' cells were found in splenic 
l' cell areas. while non-T populations lodged in splenic B 
cell follicles and red pulp, regardless of CL-LP or Control 
LP treatment (Fig. 28), indicating that migration patterns 
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Figure 1. Efficacy of in vivo LP-CL treatment. (A) LP-CL or Control-LP was injected into BN animals at -10 and -7 days of 
analysis at a dose of 4_0 mLlkg (relevant to 100 mg/kg clodronate). The spleen sections were obtained at 7 days after the last 
liposome injection and stained with mAb for CD68 (ED I), CDl63 (ED2). or CDllc with Cy3-conjugated goat anti·mouse IgG as 
secondary antibody (Ab) (red) to determine the efficacy to deplete phagocytes. The nucleus was stained with Hoechst dye (blue)_ 
Control·LP-treated animals showed normal distribution/frequency of EDI, ED2. and CDllc+ cells as seen in naive animals. 
LP-CL-treated animals demonstrated successful elimination of host APC; EDl + and ED2+ macrophages and CDllc+ DC normally 
found in the splenic red pulp, marginal zone, and periarteriolar lymphoid sheaths (PALS) disappeared after treatment. The 
numbers of EDl +, ED2+, or CDllc+ cellslhigh power Held (HPF: X400) in the spleen of Control-LP- or LP-CL-treated recipients 
(n = 3 each) were counted and shown in bar graphs. Original magnification; x 400. (B) MLR of splenocytes obtained from 
LP-CL-treated animals. Splenocytes of LP·CL·treated animals (n = 3) at 7 days after la"t Iiposome injection showed intact 
proliferative capacity against allogenic stimulator cells in MLR. 
were not aJtered by LP-CL Lrealmenl. Most injected 
CFSE + cells disappeared by 72 hours of injection in non-
immunosuppressed recipienls (data not shown). 
LP-CL Recipient Treatment Reduced IFN-l' Up-
Regulation After Allogenic Cell Injection 
Type 1 helper T cell (Th 1) type immune response was 
anaJyzed in the spleen at 24 and 72 hours after aJlogenic 
cell injection to determine lhe effects of host phagocyte 
depletion. mRNA levels (or IFN-)' dramatically increased 
in animaJs treated with Control-LP, and the non-T cell 
populalion induced stronger IFN-)' mRNA up-regulation 
than the T cell population (Fig. 2C). In contrast. animaJs 
treated VJith LP-CL showed Significantly lower IFN-)' 
mRNA increases afterT or non-T cell injection. The result 
suggests the considerable impact of depletion of host 
phagocytic cells VJith LP-CL treatment on early cytokine 
responses. There was no significant difference in IL-2 
mRNA levels among groups. mRNA levels for IFN-)' were 
reducecl lo the baseline levels by 72 hours after injection. 
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Figure 2, Real-time visualization and migration pattern of infused Ccpb~ allogenic cell and subsequent Thl cytokine mRNA 
up-regulation in the spleen. (A) Sequential real-time tracking images of infused CFSE labeled LEW splenocytes were captured in 
host BN spleen using in vivo confocal Ouorescent microscopy_ Infused allogenic cells immedIately migrated to host spleen and 
promptly localized at !ltable pO!lition!l. The number of lodged Ccpb~ cell!l increased with time (original magnification: approx-
imately X400). (B) Migration patterns of CFSE-labeled LEW T cell!l or non-Tcell!l (2 x 108 cells per animal) were analyzed in the 
spleen of recipients treated with Control-LP or LP-CL (40 mLlkg at -10 and -7 days). The spleen !lamples were stained with 
phycoerythrin (PE}-conjugated R7.3 mAb to mark the T cell area [periarteriolar lymphOid !lheaths (PALS). red]. At I day. infu!led 
CFSE' (green) T cells were found in the T cell area. while non-T cells lodged in B cell foUicle!l and red pulps in control recipients_ 
In LP-CL recipients. the migration patterns were not altered. and allogenic T cell!l and non-T cells were found in T cell area and 
B cell follicles/red pulps. respectively (original magnification: x 100). (C) mRNA levels of cytokines in the hO!lt spleen. Splenic Th I 
type immune respon!le wa!l examined by real time RT-PCR at I and 3 day" after cell infusion into BN recipients treated with 
Control-LP (C) or LP-CL (n = 3-4 in each group and each time point). Values were shown as fold increase versu!l normal spleen . 
• p < 0.01; "P < 0.05; ·"P < 0.001. 
LP-CL Recipient Treatment Augmented Anti-
Donor Alloimmune Responses After LT 
Host phagocytic cell elimination could modify all osen-
sitizaLion. a nd in vivo inf1uence of host LP-CL trea tment 
was examined by conducting allogenic LT into LP-LC-
treated reCipients. Without immunosuppression, LEW 
live r allogralt survival in ControJ-LP-treated BN reCipi-
ents was 23.5 days (median. n = 4). In LP-CL-treated 
EN reCipients, LEW liver graft survival was slightly 
shorter. with a med ia n of 17.5 days [n = 4): however. no 
statistical difference was observed. When recipients 
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Figure 3. Histopathology and characterization of donor-de-
rived MHC class 11+ cells in liver allograft at 100 days after 
OL Tx_ At 100 days after OL Tx. liver allografts were obtained 
from Control-LP- or LP-CL-treated BN recipients and exam-
ined by routine histopathology and immunohistochemistry 
with donor MHC class II mAb (L21-S). (A) Hematoxylin and 
eosin (H&E)-stained section showed that liver grafts in control 
Ileft) were free from chronic rejection ICR). In the LP-CL group 
(right). the liver allografts were essentially normal. but mild 
lymphocytic infiltration in the portal triad was more promi-
nent (original magnification: x200). (B) L21-6+ donor MHC 
class 11+ cells (brown) were found in the portal triad of control 
liver graft (left). while they totally disappeared from liver 
grafts in LP-CL-treated recipients (right). Biliary epithelial 
cells in the LP·CL group were positive for L21·S (original 
magnification: x 200). (C) Further characterization of donor 
MHC class 11+ cells by double immunofluorescence using Cy3-
conjugated L21·6 Ired) demonstrated that the majority of 
L21·6+ cells were COlIc (green) positive DC. There were few 
L21-6+IED2+ and L21·6+f1gM+ cells (original magnification: 
XSOO). Representative images of 4 experiments. 
were Lrealed with a short course of TAC immunosup-
pression 11 .0 mg/kg on days 0-6. 13. and 20). liver 
a llograll survival was prolonged Lo > 100 days in both 
Control-LP- and LP-CL-trealed reCipients (n = 8 for 
each) . Histopathological analysis of liver allografts at 
100 days revealed lhaL liver allografts in the Control- LP 
groLlp were Iree irom chronic rejeclion (Fig. 3A. lell). as 
previously reporled in naive BN recipienLs 2G Liver allo-
.[(rarts in the LP-CL group aL 100 days also showed 
essenlially normal hepatic archiLecture: however. Iym-
phoevlic in/iltl-ation in the porU\! Lriad was more evident 
lhan in the Control-LP groLlp (Fig. 3A. right). 
A re markable dilTerence between the Control-LP and 
LP-CL groups. however. was noticed in the frequency of 
donor MHC class I1+ (L21-6+) cells maintained in the 
liver allografts (Fig. 3B). At 100 days. liver allografts in 
Control-LP group showed abundant L21-6 ,. cells in the 
portal triad with a similar distribution pattern and fre-
quency seen in naive LEW liver (Fig. 3B. left): this find-
ing was consistent with our previOUS study using naive 
BN as recipients. 35 Further analysis using double im-
munofluorescence confirmed that the majority of 
L21-6 + cells perSisting in liver allografts were CD II c + 
DC (Fig. 3C. left) with few ED2' Kupffer cells (Fig. 3C. 
middle) and IgM + B cells (Fig. 3C . right). rn contrast. 
almost all L21-6 ·' cells disappeared from liver allografts 
in LP-CL-treated reCipients at 100 days. Instead. the 
biliary epithelial cells in liver allografts became L21-6+. 
indicating the up-regUlation of MHC class II on graft 
bile ducts due to alloimmune reactions (Fig. 3B, right). 
Donor MHC Class II Disappeared Early After 
LT in LP-CL-Treated Recipients 
To investigate whether the difference in the number of 
L21-6+ cells in the liver allografts took place during the 
early posttransplantation period. liver grafts and host 
spleens were analyzed I and 7 days after transplanta-
tion . In liver allografts in LP-CL-treated reCipients. al-
most all L21-6 + cells disappeared by 7 days after OLTx. 
while donor MHC class II < cells were found in the portal 
triad of liver grafts in Control-LP-treated reCipients at 7 
days alter OLTx (Fig. 4A). 
Likewise. in the host spleen. at I day after OLTx, 
L21-6+ cells were detected in the red pulp. periarterio-
lar lymphoid sheath. and marginal zone in both groups 
(Fig. 4A); however. by 7 days, L21-6+ cells in LP-CL-
treated reCipients mostly disappeared from the spleen. 
Significantly more donor MHC class Ir cells remained 
in the spleen of control reCipients (Fig. 4B). 
Early Cytokine Up-Regulation Was Inhibited 
in LP-CL-Treated Recipients 
Splenic mRNA levels for IFN -"I and IL-2 increased in 
Control-LP-treated reCipients at I day after OLTx under 
TAC . while LP-CL-treated reCipients showed a signifi-
cant reduction of IFN--y and IL-2 up-regUlation (Fig. 5). 
There was no difference in splenic mRNA expression of 
IL-IO. By 7 days. mRNA level s decreased to near base-
line levels in both groups of reCipients . 
Donor Strain Challenge HTx Into Liver 
Allograft Recipients 
Although both groups of liver allografts survived > 100 
days. there was an apparent difference in the presence 
of donor MHC class ll+ (L21-6 +) cells in liver allografts 
due to LP-CL treatment. To determine if the disappear-
ance of donor MHC class II + cells caused further 
changes in recipient anti-donor immune responses , we 
challenged BN reCipients bearing LEW liver allograft 
with LEW donor heart grafts at 100 days after OL Tx. 
Heart grafts in both the Control-LP (n = 3) and LP-CL 
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Figure 4. Donor MHC class 11+ ceU migration early after 
OLTx. (A) Upper: At 7 days after OLTx under TAC. L21-6+ 
ceUs (donor MHC class 11+ DC) were found in the portal triad of 
control liver grafts. In contrast. L21-6+ ceUa disappeared 
Crom liver grafts of LP-CL-treated recipients at 7 days_ Immu-
noCluorescent staining with Cy3-conjugated L21-6 (red) (orig-
inal magnification: x 200). Middle and lower: In host spleen. 
at 1 day after OL Tx. L21-6 + ceUs were detected in the red 
pulp. peri arteriolar lymphoid sheath (PALS). and marginal 
zone in both Control-LP and LP-CL-treated recipients. How-
ever. at 7 days after OLTx. donor L21-6+ ceUs in LP-CL-
treated recipients mostly disappeared Crom the spleen. while 
significant numbers oC L21-6+ ceUs remained in the spleen of 
control recipients. Double immunofluorescence using Cy3-
conjugated L21-6 (red) and FITC-conjugated anti-rat IgM 
(green) with nuclear Hoechst dye (Blue). BF. B ceU follicle 
(lgM+I; MZ. marginal zone; p. periarteriolar lymphoid sheath 
(PALS). (D) The number of donor L21-6+ ceUslhigh power field 
(HPF) in Control-LP- or LP-CL-treated recipient spleen at 1 
and 7 days after OLTx (n = 4 in each time pOint). 'P < 0.05. 
Control-LP versus LP·CL. 
(n = 4) groups survived for> 100 days. However. heart 
grafts in the Control-LP group appeared to beat more 
vigorously than those in the LP-CL group. Histopatho-
logical analysis revealed that cardiac challenge allo-
grafts in tl1e Control-LP group were essentially normal 
(Fig. 6A. left). whereas those in LP-CL group had mod· 
erate endocardia!. pericardia!. interstitial. and minimal 
periarterial mononuclear aggregation !Fig. 6A. right). 
Furthermore. L21 -6 stain of challenge heart grafts in 
the Control-LP group showed homogeneous distribu-
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tion of spindle-shaped interstitial donor MHC class II+ 
cells through the myocardium with a frequency of 
18.6 ::':: 5.7 cells/high power field. as seen in naive heart 
(Fig. 6B, left). On the other hand. no definite L21-6+ 
interstitial ce lls were found in challenge heart grafts in 
the LP-CL group. In this group. L21-6 staining was seen 
on the vascular endothelial celis, indicating MHC class 
II up-regUlation due to rejection (Fig. 6B. right). 
MLR was conducted at different time pOints before 
and after challenge HTx. At 100 days after OL Tx (beCore 
challenge HTx), lymphocytes from Control-LP-treated 
reCipients demonstrated donor-specific hyporespon-
siveness. LP-CL-treated reCipients showed Significantly 
higher proliferative responses to donor strain stimula-
tor cells compared with control reCipien ts . although 
anti-donor proliferation was low compared to responses 
to third party stimulator ce lls. Both groups of reCipients 
showed lower anti-donor (LEW) proliferation when com-
pared to that of naive BN (Fig. 7). Nter donor strain 
challenge heart grafting, in vitro anti-donor reactivity 
was further enhanced in reCipients in the LP-CL group. 
At 100 days after challenge HTx (200 days after OLTx), 
although reCipients in the Control-LP group maintained 
donor-speCific hyporeactivity. LP-CL-treated reCipients 
showed significantly (P < 0.05) increased proliferation 
to donor antigens compared to Control-LP-treated re-
Cipients. 
LP-CL Treatment Abrogated Spontaneous 
Acceptance of Liver Allografts 
To further assess the effects of host phagocyte depletion 
on in vivo LToutcomes, we next applied recipient LP-CL 
pretreatment (4 mL/kg on days -7 and -10) in the 
model of spontaneous liver allograft acceptance. When 
Control-LP-pretreated LEW reCipients received BN liver 
allografts, all liver grafts were accepted without immu-
nosuppression, and reCipients survived for > 100 days. 
In contrast. with BN liver grafts transplanted into LP-
CL-treated recipients. 4 of 7 (57%) died within 32 days 
"':t.r • : o--oc ~ ·K m ; ~ ;> '''; l 
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Figure 5. mRNA levels for cytokines in the spleen by real-time 
RT·PCR. Spleen samples were obtained from control (n = 4) 
and LP-CL reCipients (n = 4) at 1 and 7 days after OL Tx under 
TAC Immunosuppression. At 1 day after OLTx. mRNA levels 
Cor IFN-'Y and IL-2 were significantly lower in LP·CL recipients 
than in control recipients. However. IL-IO mRNA levels were 
not altered. By day 7 after OL Tx. IFN-'Y and IL-2 mRNA levels 
retarned to the baseline values. Valuell were shown as fold 
Increase compared to normal spleen (open bar). 'P < 0.05. 
Control-LP verllus LP-CL. 
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Figure 6. Histopathology and donor MHC class 11+ cells in 
challenge heart allografts. At 100 days after OL Tx in Control· 
Lp· or LP-CL-treated BN animals. LEW challenge heart grafts 
were placed. After following additional 100 days, heart allo-
grafts were obtained for routine histopathology and donor 
MHC class 11+ stain. (A) Hematoxylin and eosin (H&E)-stained 
sections of cardiac challenge allografts in Control-LP-treated 
recipients showed essentially normal architecture. In con-
trast, challenge heart grafts in LP-CL-treated recipients had 
moderate endocardial. pericardial. interstitial, and minimal 
periarterial mononuclear aggregation (original magnification: 
x 200). (B) In challenge heart allografts from Control-LP-
treated recipients. L21-6+ spindle-shaped interstitial cells 
(brown) were easily found [18.6 ± 5.7 cellslhigh power field 
(HPF)J. No definite L21-6+ cells were found in challenge heart 
grafts of LP-CL-treated recipients. Instead. endothelium of 
the coronary artery showed L21-6 positivity (MHC class II 
up-regulation) (original magnification X200). Representative 
images of 4 experiments. 
(Fig. 8). The result indicated the beneficial roles of host 
phagocytes in inducing liver allograft acceptance in this 
model. 
DISCUSSION 
This study demonstrated the influence of host splenic 
phagocyte depletion with LP-CL on alloimmune re-
sponses aner LT. In the LEW to BN rat LT model. the 
lack of host cells capable of phagocytosing alloantigens 
and presenting them to host T cells during the early 
posttransplantation period resulted in an inferior de-
gree of liver allograft acceptance. Under a therapeutic 
dose of TAC immunosuppression, histopathological 
analyses and in vitro T cell proliferative assays showed 
Significant anti-donor alloreactivity in LP-CL-treated 
liver reCipients compared to those in Control-LP-treated 
recipients. The finding was further substantiated in the 
model of spontaneous liver allograft acceptance; BN 
liver allografts. which normally were accepted in LEW 
rat recipients \vithout immunosuppression. 30 were re-
jected in 57% of LP-CL-treated recipients. 
Mter LT. Thl cytokines have been shown to be up-
regulated in the spleen mainly by host T cells. 37 In this 
study. lhe lack of host phagocytes in LP-CL-treated 
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Figure 7. One-way MLR after OL Tx and subsequent challenge 
HTx. At 100 days after OL Tx and just before challenge HTx, 
lymphocytes from Control-LP- and LP-CL-treated recipients 
demonstrated donor-specific hyporesponsiveness; however, 
LP-CL-treated recipients showed significantly higher anti-do-
nor proliferative responses compared with Control-LP-treated 
recipients. Anti-donor proliferative reactivity increased in re-
cipients in the LP-CL group after donor strain challenge HTx. 
At 100 days after HTx (200 days after OLTx). Control-LP-
treated recipients maintained donor-specific hyporeactivity, 
and LP-CL-treated recipients showed significantly increased 
proliferation to donor antigens compared to Control-LP-
treated recipients (*P < 0.05). n = 3-4 for each group. 
liver transplant recipients during the early posttrans-
plantation period resulted in a significant reduction of 
mRNA levels for Thl cytokines (INF-'Y and IL-2) in the 
spleen. Likewise. allogeniC cell infusion into LP-CL-
treated recipients was associated with reduced Thl cy-
tokine up-regulation and less T cell proliferation com-
pared to those in Control-LP-treated reCipients. Thus, 
the elimination of host phagocytes early after allogeniC 
organ/ cell transplantation resulted in reduced host T 
cell activation and cytokine up-regulation. suggesting 
that early T cell activation after organ/ cell transplanta-
tion might involve the indirect pathway of allorecogni-
100 ~----~--------------------------~4 
80 
ro 
> 60 c: 
::J 40 (/) 
~ <> 
20 
0 0 20 40 60 80 100 
Days after BN to LEW OL Tx 
Figure 8. BN liver allograft survival in LEW rats. All Control-
LP-treated LEW recipients survived for > 100 days after 
transplantation of BN liver allografts (n = 8). In contrast. the 
survival was significantly (P <.05) impaired. when reCipient 
phagocytes were depleted with LP-CL treatment (- 10 and -7 
days before liver transplant). and 4 of 7 reCipients pretreated 
with LP·CL died within 35 days after transplantation. 
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tion via host phagocytes. The importance of indirect 
all ore cognition in the acute phase of organ transplan-
tation has been previously examined in several experi-
mental studies using genetically engineered mice. 12-
1-'-:lS [n a single MHC discordance model. cardiac or 
skin aUo,grafts from human leukocyte antigen-A2-
transgenic C57BL/6 mice were acutely rejected in nor-
mal C57BL/6 mice. and it was suggested that indirect 
allorecognition of donor MHC class I molecules led to 
the development of alloantibodies and allograft rejec-
tion. 1:3.14 In other studies using MHC class II transac-
tivator [CIlTA)-dellcient mice as the donor. cardiac or 
skin allografts from CIITA-I- mice were acutely re-
jected in unmodified and CDS-depleted reCipients. 12.3n 
Because CIITA -1- allografts were not able to directly 
present class II alloantigens to host CD4 ' T cells, the 
rejection response was believed to be due to host CD4 + 
T cells responding to indirectly presented alloantigens 
by host APC. In agreement with these studies in genet-
ically engineered mice. the current study using normal 
inbred rats may suggest that host phagocytic cells and 
indirect allorecognition could play roles in acute phase 
alloimmune responses after LT. 
An interesting finding in this study was the early loss 
of donor MHC class W- cells and the development of 
signiiicant anti-donor alloreactivity in LP-CL-treated 
reCipients. In control liver recipients with normal host 
phagocyte [unction. numerous donor MHC class rr 
cells perSisted for >200 days in the spleen and portal 
triads of liver allografts. as we have previously report-
ed.26.:35A0.41 Persisting donor MHC class III cells in the 
liver allografts showed a similar frequency and distri-
bution pattern as that seen in the normal liver and 
included CD 11c + donor DC. However, in reCipients 
treated with LP-CL, donor MHC class n+ cells quickly 
disappeared from the liver allograft and host spleen, 
which is associated with the loss of typical hepatic tol-
erance. Because LP-CL was administered to recipients 
7 days before LT. LP-CL unlikely had a direct elIect in 
eliminating donor MHC class II i cells after transplan-
tation. The previous study by Buiting et al. 29 showed 
that the concentration of clodronate in the blood. liver. 
spleen. and lung increased after LP-CL injection with 
the peak at 0.5 hour. However. clodronate levels quickly 
decreased thereafter and became baseline by 24 hours. 
Fleisch42 also showed the rapid clearance of free clodr-
onate rrom the body by renal excretion. The data sug-
gests that there is almost no residual LP-CL in the 
reCipient at the time ofLT (7 days after LP-CL injection). 
Alternatively. the disappearance of donor MHC class II+ 
cells could be due to anti-donor alloimmune reactions 
in LP-CL-treated recipients of liver allografts. However. 
LP-LC reCipient treatment resulted in reduced early an-
ti-donor immune reactions. determined by Th1 type 
cytokine up-regulation and T cell proliferation. thus the 
early loss of donor MHC class II+ cells in LP-CL-treated 
recipients unlikely was a direct consequence of alloim-
mune responses. 
Accordingly. the study might suggest that host 
phagocytes are required for the survival of donor leu-
kocytes. in particular MHC class 1I + hepatic DC. Solu-
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ble and membrane-bound signals are require in main-
taining the phenotype. maturation, and function of DC. 
and experimental studies have identified diverse vari-
eties of cytokines. chemokines, and growth factors that 
can affect DC homeostasisK4~ DC are sensitive to envi-
ronmental changes. and host phagocyte depletion with 
LP-CL treatment could significantly alter local microen-
vironment. Macrophages and DC produce numerous 
cytokines (e.g., IL-3. IL-6). chemokines. and growth fac-
tors [e.g., granulocyte-macrophage colony-stimulating 
factor (GMCSF)). which might be necessary to sustain 
donor cells aller transplantation. GMCSF has been 
known to have antiapoptotic action on DC. and LP-CL-
induced DC apoptosis was prevented with exogenous 
GMCSF. 21 Although further studies are required. it is 
tempting to speculate that early loss of donor MHC 
class II' cells in the environment lacking host phago-
cytes in LP-CL-treated reCipients might be due to the 
lack of signals to sustain these cells. 
Reduced early alloimmune responses in LP-CL-
treated reCipients and subsequent failure in developing 
tolerance might suggest an active role of early Thl cy-
tokines and T cell proliferation for tolerance induction. 
This finding is a reminiscence of previous studies using 
mice deficient for these cytokines. IL-2-deficient or INF-
'I-defiCient mice failed to engraft allografts or induce 
tolerance under immunosuppression. which otherwise 
resulted in long-term heart allograft acceptance.44-46 
The generation and function of alloantigen-reactive T 
regulatory cells for the development of operational tol-
erance to donor alloantigens were also shown to be 
impaired in INF--y-deficient mice.47 
Alternatively. the inferior level of liver allograft accep-
tance in recipients treated with LP-CL in this study may 
suggest the contributory role of recipient phagocytes in 
developing liver transplant tolerance. Macrophages/ 
monocytes and DC are known to produce immunosup-
pressive molecules. such as lL-1 0 and tryptophan ca-
tabolizing indoleamine 2. 3-dioxygenase.48-5o In this 
study, LP-CL treatment might abrogate immunosup-
pressive signals from macrophages and DC and fail to 
regulate T cells to develop grall acceptance. 
The application of the LP-CL method to deplete 
phagocytic cells certainly has its limitations because 
the method targets only the liver and spleen and does 
not have efficacy in lymph nodes due to the inability of 
liposomes to cross capillary walls. Hl. 17 However. using 
an in vitro whole-organ transplant system, the study 
demonstrated the significant roles of host cells with 
phagocytic capability in the spleen. Although there are 
several possible mechanisms for how phagocytic cells 
contribute to hepatic allograft acceptance. the indirect 
pathway of allorecognition during early posttransplan-
tation period might play roles in determining alloim-
mune reactions after LT. 
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